Prescribing information, details of adverse event reporting and indications can be found at the bottom of this page. BIKTARVY® is subject to additional monitoring ▼ in Great Britain; this requirement no longer applies in Ireland and Northern Ireland.
This year’s annual BHIVA Spring Conference was held over three sunny days in Gateshead, attracting a range of attendees in the HIV field.
Here you can find key data from Gilead-sponsored studies that were presented at BHIVA Spring 2023.
Weight and metabolic parameters: An increase in weight and in levels of blood lipids and glucose may occur during antiretroviral therapy, which may in part be linked to disease control and lifestyle. Lipid disorders should be managed as clinically appropriate.
Recorded: November 30th 2022
Duration: 3 mins
First presented: ID Week 2022
Watch Dr Calvin Cohen (Gilead Sciences) explain the 5-year outcomes from studies in treatment-naïve people living with HIV receiving B/F/TAF, according to baseline HIV-1 RNA and CD4 count.
Recorded: November 30th 2022
Duration: 4 mins
First presented: HIV Glasgow 2022
Watch Dr Calvin Cohen (Gilead Sciences) recount the data and key takeaways from the open-label extensions of two studies of B/F/TAF in treatment-naïve people living with HIV.
Recorded: June 29th 2023
Duration: 3 mins
First presented: GeSIDA 2022
Watch a brief animation on the results from BICSTaR, the real-world study of Biktarvy use in Europe, Canada, Japan and Israel, with data cut from February 2022.
UK-BVY-0708 Date of preparation June 2024
